BR9406941A - Formulação oral com revestimento entèrico processo para a preparação da formulação processo para a inibição da secreção de acido gástrico em mamiferos e no homem e processo para o tratamento de doencas relacionados ao ácidos gástrico em mamiferos e no homem - Google Patents
Formulação oral com revestimento entèrico processo para a preparação da formulação processo para a inibição da secreção de acido gástrico em mamiferos e no homem e processo para o tratamento de doencas relacionados ao ácidos gástrico em mamiferos e no homemInfo
- Publication number
- BR9406941A BR9406941A BR9406941A BR9406941A BR9406941A BR 9406941 A BR9406941 A BR 9406941A BR 9406941 A BR9406941 A BR 9406941A BR 9406941 A BR9406941 A BR 9406941A BR 9406941 A BR9406941 A BR 9406941A
- Authority
- BR
- Brazil
- Prior art keywords
- mammals
- man
- gastric acid
- formulation
- inhibition
- Prior art date
Links
- 238000009472 formulation Methods 0.000 title abstract 4
- 238000000034 method Methods 0.000 title abstract 4
- 239000000203 mixture Substances 0.000 title abstract 4
- 241000124008 Mammalia Species 0.000 title 2
- 201000010099 disease Diseases 0.000 title 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 title 1
- 239000002702 enteric coating Substances 0.000 title 1
- 238000009505 enteric coating Methods 0.000 title 1
- 210000004211 gastric acid Anatomy 0.000 title 1
- 230000027119 gastric acid secretion Effects 0.000 title 1
- 230000005764 inhibitory process Effects 0.000 title 1
- 238000002360 preparation method Methods 0.000 title 1
- SUBDBMMJDZJVOS-UHFFFAOYSA-N 5-methoxy-2-{[(4-methoxy-3,5-dimethylpyridin-2-yl)methyl]sulfinyl}-1H-benzimidazole Chemical compound N=1C2=CC(OC)=CC=C2NC=1S(=O)CC1=NC=C(C)C(OC)=C1C SUBDBMMJDZJVOS-UHFFFAOYSA-N 0.000 abstract 1
- 239000003814 drug Substances 0.000 abstract 1
- 159000000003 magnesium salts Chemical class 0.000 abstract 1
- 238000004519 manufacturing process Methods 0.000 abstract 1
- 229960000381 omeprazole Drugs 0.000 abstract 1
- 239000008203 oral pharmaceutical composition Substances 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
- A61K9/2886—Dragees; Coated pills or tablets, e.g. with film or compression coating having two or more different drug-free coatings; Tablets of the type inert core-drug layer-inactive layer
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
- A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
- A61K9/5073—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals having two or more different coatings optionally including drug-containing subcoatings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
Landscapes
- Health & Medical Sciences (AREA)
- Public Health (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- General Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Animal Behavior & Ethology (AREA)
- Epidemiology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Organic Chemistry (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Plural Heterocyclic Compounds (AREA)
- Medicinal Preparation (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
SE19939302395A SE9302395D0 (sv) | 1993-07-09 | 1993-07-09 | New pharmaceutical formulation |
PCT/SE1994/000681 WO1995001783A1 (en) | 1993-07-09 | 1994-07-08 | New pharmaceutical formulation |
Publications (1)
Publication Number | Publication Date |
---|---|
BR9406941A true BR9406941A (pt) | 1996-09-10 |
Family
ID=20390587
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
BR9406941A BR9406941A (pt) | 1993-07-09 | 1994-07-08 | Formulação oral com revestimento entèrico processo para a preparação da formulação processo para a inibição da secreção de acido gástrico em mamiferos e no homem e processo para o tratamento de doencas relacionados ao ácidos gástrico em mamiferos e no homem |
Country Status (40)
Country | Link |
---|---|
US (1) | US5690960A (pt) |
EP (1) | EP0706378B1 (pt) |
JP (1) | JP3665334B2 (pt) |
KR (1) | KR100350203B1 (pt) |
CN (1) | CN1126946A (pt) |
AT (1) | ATE231719T1 (pt) |
AU (1) | AU681686B2 (pt) |
BR (1) | BR9406941A (pt) |
CA (1) | CA2166483C (pt) |
CZ (1) | CZ290323B6 (pt) |
DE (1) | DE69432076T2 (pt) |
DK (1) | DK0706378T3 (pt) |
DZ (1) | DZ1794A1 (pt) |
EE (1) | EE03148B1 (pt) |
EG (1) | EG22373A (pt) |
ES (1) | ES2191682T3 (pt) |
FI (1) | FI114008B (pt) |
HK (1) | HK1008299A1 (pt) |
HR (1) | HRP940386B1 (pt) |
HU (1) | HU226779B1 (pt) |
IL (1) | IL110189A0 (pt) |
IS (1) | IS2034B (pt) |
LV (1) | LV13140B (pt) |
MA (1) | MA23258A1 (pt) |
MX (1) | MX9405219A (pt) |
MY (1) | MY128809A (pt) |
NO (1) | NO315146B1 (pt) |
NZ (1) | NZ268694A (pt) |
PL (1) | PL175210B1 (pt) |
RU (1) | RU2138254C9 (pt) |
SA (1) | SA94150057B1 (pt) |
SE (1) | SE9302395D0 (pt) |
SG (1) | SG52365A1 (pt) |
SI (1) | SI0706378T1 (pt) |
SK (1) | SK281105B6 (pt) |
TN (1) | TNSN94078A1 (pt) |
UA (1) | UA43342C2 (pt) |
WO (1) | WO1995001783A1 (pt) |
YU (1) | YU49199B (pt) |
ZA (1) | ZA944934B (pt) |
Families Citing this family (98)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US6875872B1 (en) * | 1993-05-28 | 2005-04-05 | Astrazeneca | Compounds |
SE9301830D0 (sv) * | 1993-05-28 | 1993-05-28 | Ab Astra | New compounds |
SE9302395D0 (sv) * | 1993-07-09 | 1993-07-09 | Ab Astra | New pharmaceutical formulation |
ATE206044T1 (de) * | 1994-07-08 | 2001-10-15 | Astrazeneca Ab | Aus mehreren einzeleinheiten zusammengesetzte dosierungsform in tablettenform (i) |
CA2193681A1 (en) * | 1994-07-08 | 1996-01-25 | Astra Aktiebolag | New oral pharmaceutical formulation containing magnesium salt of omeprazole |
SE9402431D0 (sv) * | 1994-07-08 | 1994-07-08 | Astra Ab | New tablet formulation |
SE9500478D0 (sv) * | 1995-02-09 | 1995-02-09 | Astra Ab | New pharmaceutical formulation and process |
CR5278A (es) * | 1995-03-24 | 1996-07-04 | Lilly Co Eli | Formulacion oral de 2-metil-tieno-benzodiacepina |
US5945124A (en) * | 1995-07-05 | 1999-08-31 | Byk Gulden Chemische Fabrik Gmbh | Oral pharmaceutical composition with delayed release of active ingredient for pantoprazole |
US6489346B1 (en) | 1996-01-04 | 2002-12-03 | The Curators Of The University Of Missouri | Substituted benzimidazole dosage forms and method of using same |
US6699885B2 (en) | 1996-01-04 | 2004-03-02 | The Curators Of The University Of Missouri | Substituted benzimidazole dosage forms and methods of using same |
US6645988B2 (en) | 1996-01-04 | 2003-11-11 | Curators Of The University Of Missouri | Substituted benzimidazole dosage forms and method of using same |
US5840737A (en) | 1996-01-04 | 1998-11-24 | The Curators Of The University Of Missouri | Omeprazole solution and method for using same |
SE512835C2 (sv) * | 1996-01-08 | 2000-05-22 | Astrazeneca Ab | Doseringsform innehållande en mångfald enheter alla inneslutande syralabil H+K+ATPas-hämmare |
SE508669C2 (sv) * | 1996-04-26 | 1998-10-26 | Astra Ab | Nytt förfarande |
DE19626045C2 (de) * | 1996-06-28 | 1998-12-03 | Klinge Co Chem Pharm Fab | Stabile Arzneiform zur oralen Verabreichung, welche Omeprazol als aktiven Wirkstoff enthält, sowie Verfahren zur Herstellung derselben |
US6623759B2 (en) | 1996-06-28 | 2003-09-23 | Astrazeneca Ab | Stable drug form for oral administration with benzimidazole derivatives as active ingredient and process for the preparation thereof |
IL128845A0 (en) * | 1996-09-24 | 2000-01-31 | Lilly Co Eli | Coated particle formulation |
TW385306B (en) * | 1996-11-14 | 2000-03-21 | Takeda Chemical Industries Ltd | Method for producing crystals of benzimidazole derivatives |
JP2001524131A (ja) * | 1997-05-09 | 2001-11-27 | セイジ、ファーマスーティカルズ、インク | 安定な経口医薬品剤形 |
SE9702000D0 (sv) * | 1997-05-28 | 1997-05-28 | Astra Ab | New pharmaceutical formulation |
US6747155B2 (en) | 1997-05-30 | 2004-06-08 | Astrazeneca Ab | Process |
SE510650C2 (sv) | 1997-05-30 | 1999-06-14 | Astra Ab | Ny förening |
SI9700186B (sl) | 1997-07-14 | 2006-10-31 | Lek, Tovarna Farmacevtskih In Kemicnih Izdelkov, D.D. | Nova farmacevtska oblika z nadzorovanim sproscanjem zdravilnih ucinkovin |
US20050244497A1 (en) * | 1997-11-05 | 2005-11-03 | Wockhardt Limited | Delayed delivery system for acid-sensitive drugs |
US6174548B1 (en) | 1998-08-28 | 2001-01-16 | Andrx Pharmaceuticals, Inc. | Omeprazole formulation |
US6096340A (en) * | 1997-11-14 | 2000-08-01 | Andrx Pharmaceuticals, Inc. | Omeprazole formulation |
WO1999027917A1 (de) * | 1997-11-28 | 1999-06-10 | Byk Gulden Lomberg Chemische Fabrik Gmbh | Arzneimittelzubereitung in tabletten- oder pelletform für säurelabile wirkstoffe |
SE9704870D0 (sv) | 1997-12-22 | 1997-12-22 | Astra Ab | New pharmaceutical formulation I |
US20020039597A1 (en) * | 1998-04-20 | 2002-04-04 | Koji Ukai | Stabilized compositions containing benzimidazole-type compounds |
UA73092C2 (uk) * | 1998-07-17 | 2005-06-15 | Брістол-Майерс Сквібб Компані | Таблетка з ентеросолюбільним покриттям і спосіб її приготування |
US7094426B2 (en) * | 1998-08-27 | 2006-08-22 | Sage Pharmaceuticals, Inc. | Stable oral pharmaceutical dosage forms |
US6733778B1 (en) | 1999-08-27 | 2004-05-11 | Andrx Pharmaceuticals, Inc. | Omeprazole formulation |
SE9803772D0 (sv) * | 1998-11-05 | 1998-11-05 | Astra Ab | Pharmaceutical formulation |
UA72748C2 (en) * | 1998-11-10 | 2005-04-15 | Astrazeneca Ab | A novel crystalline form of omeprazole |
IL142703A (en) * | 1998-11-10 | 2006-04-10 | Astrazeneca Ab | Crystalline form of omeprazole |
DK1131316T3 (da) | 1998-11-18 | 2004-09-27 | Astrazeneca Ab | Forbedret kemisk fremgangsmåde og farmaceutisk præparat |
US6365128B1 (en) * | 1998-12-18 | 2002-04-02 | Medical Defence Technologies, Llc | Monitoring gastrointestinal function to guide care of high risk patients |
MXPA01009934A (es) * | 1999-03-29 | 2002-06-21 | American Home Prod | Sistema de recubrimiento. |
IL130602A0 (en) * | 1999-06-22 | 2000-06-01 | Dexcel Ltd | Stable benzimidazole formulation |
SE9902386D0 (sv) * | 1999-06-22 | 1999-06-22 | Astra Ab | New formulation |
US6245913B1 (en) | 1999-06-30 | 2001-06-12 | Wockhardt Europe Limited | Synthetic procedure for 5-methoxy-2-[(4-methoxy-3,5-dimethyl-2-pyridinyl)-methylthio]-IH-benzimidazole hydrochloride and its conversion to omeprazole |
US6500459B1 (en) * | 1999-07-21 | 2002-12-31 | Harinderpal Chhabra | Controlled onset and sustained release dosage forms and the preparation thereof |
US6316020B1 (en) * | 1999-08-26 | 2001-11-13 | Robert R. Whittle | Pharmaceutical formulations |
KR20020038759A (ko) | 1999-10-20 | 2002-05-23 | 다니구치 미즈오 | 벤즈이미다졸계 화합물 안정화 방법 |
WO2001087831A2 (en) * | 2000-05-15 | 2001-11-22 | Ranbaxy Laboratories Limited | Novel amorphous form of omeprazole salts |
ES2191521B1 (es) * | 2000-11-22 | 2005-02-16 | Laboratorios Belmac, S.A. | Nueva formulacion galenica del omeprazol en forma de comprimidos, procedimiento para su preparacion y aplicaciones en medicina humana y en veterinaria. |
US20030070584A1 (en) | 2001-05-15 | 2003-04-17 | Cynthia Gulian | Dip coating compositions containing cellulose ethers |
US8206741B2 (en) | 2001-06-01 | 2012-06-26 | Pozen Inc. | Pharmaceutical compositions for the coordinated delivery of NSAIDs |
US8309118B2 (en) | 2001-09-28 | 2012-11-13 | Mcneil-Ppc, Inc. | Film forming compositions containing sucralose |
EP2258351B1 (en) | 2001-10-17 | 2013-06-19 | Takeda Pharmaceutical Company Limited | Granules containing lansoprazole in large amount |
US20040006111A1 (en) * | 2002-01-25 | 2004-01-08 | Kenneth Widder | Transmucosal delivery of proton pump inhibitors |
AU2003209534A1 (en) * | 2002-03-08 | 2003-09-22 | Bakulesh Mafatlal Khamar | The method of treating tuberculosis |
US7429619B2 (en) | 2002-08-02 | 2008-09-30 | Mcneil Consumer Healthcare | Polyacrylic film forming compositions |
PT1524967E (pt) * | 2002-08-02 | 2008-04-03 | Ratiopharm Gmbh | Preparação farmacêutica contendo um composto de benzimidazole misturado com celulose microcristalina e método para a sua preparação. |
MY148805A (en) | 2002-10-16 | 2013-05-31 | Takeda Pharmaceutical | Controlled release preparation |
AU2003900096A0 (en) * | 2003-01-10 | 2003-02-20 | Nature Vet | Orally deliverable pharmaceutical composition protein pump inhibitors |
ITMI20030616A1 (it) * | 2003-03-28 | 2004-09-29 | Acme Drugs S R L | Metodo per la preparazione di farmaci, alimenti, integratori alimentari, gastroprotetti e/o a rilascio controllato, prodotti dietetici, premiscele per mangim,i additivi per l'alimentazione zootecnica contenenti principi attivi sensibili all'ambiente |
US8993599B2 (en) | 2003-07-18 | 2015-03-31 | Santarus, Inc. | Pharmaceutical formulations useful for inhibiting acid secretion and methods for making and using them |
AR045068A1 (es) * | 2003-07-23 | 2005-10-12 | Univ Missouri | Formulacion de liberacion inmediata de composiciones farmaceuticas |
JP2007504261A (ja) * | 2003-09-03 | 2007-03-01 | エイジーアイ・セラピューティクス・リサーチ・リミテッド | プロトンポンプ阻害剤製剤、並びに当該製剤を製造及び使用する方法関連出願の表示 |
US20050214388A1 (en) * | 2004-02-18 | 2005-09-29 | Gorham Thomas R | Multivitamin formulations containing controlled-release magnesium |
WO2005082888A1 (en) * | 2004-03-01 | 2005-09-09 | Milen Merkez Ilac Endustrisi A.S. | Process for the preparation of magnesium salt of omeprazole |
US8815916B2 (en) | 2004-05-25 | 2014-08-26 | Santarus, Inc. | Pharmaceutical formulations useful for inhibiting acid secretion and methods for making and using them |
US8906940B2 (en) | 2004-05-25 | 2014-12-09 | Santarus, Inc. | Pharmaceutical formulations useful for inhibiting acid secretion and methods for making and using them |
AU2005264864B2 (en) | 2004-06-16 | 2011-08-11 | Takeda Pharmaceutical Company Limited | Multiple PPI dosage form |
US20060024362A1 (en) * | 2004-07-29 | 2006-02-02 | Pawan Seth | Composition comprising a benzimidazole and process for its manufacture |
US8658216B2 (en) | 2004-12-23 | 2014-02-25 | Ranbaxy Laboratories Limited | Stable oral benzimidazole compositions and process of preparation thereof |
WO2006087613A2 (en) * | 2005-02-02 | 2006-08-24 | Ranbaxy Laboratories Limited | Stable oral benzimidazole compositions prepared by non-aqueous layering process |
CA2784881C (en) | 2005-02-25 | 2016-02-09 | Takeda Pharmaceutical Company Limited | Method for producing granules |
BRPI0617987A2 (pt) * | 2005-10-06 | 2011-08-16 | Auspex Pharmaceuticals Inc | composição, composição farmacêutica, forma de dosagem efervescente, composição farmacêutica oral de comprimidos unitários múltiplos, forma de dosagem farmacêutica de liberação prolongada, forma de dosagem farmacêutica revestida entérica, forma de dosagem farmacêutica estável para administração oral a sujeitos mamìferos, método para tratamento de doenças relacionadas a ácido gástrico pela inibição de secreção de ácido gástrico, método para tratamento de uma infecção bacteriana provocada ou mediada por helicobacter pylori, processo para preparar um composto da fórmula 3, processo para preparar um composto da fórmula 5, uso de um composto da fórmula 1 para a preparação de um medicamento para tratamento de doenças relacionadas a ácido gástrico, pela inibição de secreção de ácido gástrico, uso de um composto da fórmula 1 para a preparação de um medicamento para tratamento de uma infecção bacteriana provocada ou mediada por helicobacter pylori uso de um composto da fórmula 1 para a preparação de um medicamento para tratamento de doenças relecionadas a ácido gástrico pela inibição de secreção de ácido gástrico |
WO2007138606A2 (en) * | 2006-06-01 | 2007-12-06 | Dexcel Pharma Technologies Ltd. | Multiple unit pharmaceutical formulation |
AU2007276874B2 (en) * | 2006-07-28 | 2010-08-19 | Dr. Reddy's Laboratories Ltd. | Granular pharmaceutical compositions |
GB2459393B (en) | 2006-10-05 | 2010-09-08 | Santarus Inc | Novel capsule formulation for the proton pump inhibitor omeprazole |
MX2009004475A (es) | 2006-10-27 | 2009-08-12 | Univ Missouri | Composiciones que comprenden agentes acido labiles que inhiben la bomba de protones, por lo menos otro agente farmaceuticamente activo y metodos de uso de las misma. |
US20080194307A1 (en) * | 2007-02-13 | 2008-08-14 | Jeff Sanger | Sports-based game of chance |
WO2009113090A2 (en) * | 2008-01-17 | 2009-09-17 | Alkem Laboratories Ltd. | Process for preparing an oral formulation of an acid-sensitive benzimidazole drug |
US8247440B2 (en) | 2008-02-20 | 2012-08-21 | Curators Of The University Of Missouri | Composition comprising omeprazole, lansoprazole and at least one buffering agent |
US8911787B2 (en) | 2008-02-26 | 2014-12-16 | Ranbaxy Laboratories Limited | Stable oral benzimidazole compositions and process of preparation thereof |
WO2009136398A2 (en) * | 2008-05-06 | 2009-11-12 | Dexcel Ltd | Stable benzimidazole formulation |
US20090280175A1 (en) * | 2008-05-09 | 2009-11-12 | Ishwar Chauhan | Multilayer Proton Pump Inhibitor Tablets |
AU2009290712A1 (en) | 2008-09-09 | 2010-03-18 | Astrazeneca Ab | Method for delivering a pharmaceutical composition to patient in need thereof |
JP5788331B2 (ja) | 2009-01-09 | 2015-09-30 | フォーワード・ファルマ・アクティーゼルスカブForward Pharma A/S | 浸食マトリックス中に1またはそれ以上のフマル酸エステルを含む医薬製剤 |
JP2012531409A (ja) | 2009-06-25 | 2012-12-10 | アストラゼネカ・アクチエボラーグ | Nsaid関連潰瘍を発症するリスクがある患者の処置方法 |
EP2345408A3 (en) | 2010-01-08 | 2012-02-29 | Dr. Reddy's Laboratories Ltd. | Acid labile drug formulations |
WO2012174102A2 (en) | 2011-06-14 | 2012-12-20 | Medical Defense Technologies, Llc. | Methods and apparatus for guiding medical care based on detected gastric function |
BR112014016085A8 (pt) | 2011-12-28 | 2017-07-04 | Pozen Inc | composições aprimoradas e métodos para distribuição de omeprazol mais ácido acetilsalicílico |
CN103127026B (zh) * | 2013-02-05 | 2017-02-15 | 悦康药业集团有限公司 | 一种奥美拉唑肠溶胶囊及其制备方法 |
CN103735526A (zh) * | 2013-08-08 | 2014-04-23 | 上海海虹实业(集团)巢湖今辰药业有限公司 | 奥美拉唑镁肠溶片及其制作方法 |
CN103467453A (zh) * | 2013-09-13 | 2013-12-25 | 上海海虹实业(集团)巢湖今辰药业有限公司 | 一种奥美拉唑镁原料药制备方法 |
US20170042806A1 (en) | 2015-04-29 | 2017-02-16 | Dexcel Pharma Technologies Ltd. | Orally disintegrating compositions |
WO2017145146A1 (en) | 2016-02-25 | 2017-08-31 | Dexcel Pharma Technologies Ltd. | Compositions comprising proton pump inhibitors |
US10076494B2 (en) | 2016-06-16 | 2018-09-18 | Dexcel Pharma Technologies Ltd. | Stable orally disintegrating pharmaceutical compositions |
CZ2017315A3 (cs) | 2017-06-02 | 2018-12-12 | Zentiva, K.S. | Dávkovací jednotka s PPI (inhibitory protonové pumpy) |
JPWO2021153525A1 (pt) | 2020-01-27 | 2021-08-05 | ||
US11426353B2 (en) * | 2020-06-24 | 2022-08-30 | 13400719 Canada Inc. | Composite coating for an active agent |
CN113350313B (zh) * | 2021-06-23 | 2023-08-11 | 福建金山生物制药股份有限公司 | 一种艾司奥美拉唑镁延释制剂及其制备方法 |
WO2024075017A1 (en) | 2022-10-04 | 2024-04-11 | Zabirnyk Arsenii | Inhibition of aortic valve calcification |
Family Cites Families (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
SE7804231L (sv) * | 1978-04-14 | 1979-10-15 | Haessle Ab | Magsyrasekretionsmedel |
SE8301182D0 (sv) * | 1983-03-04 | 1983-03-04 | Haessle Ab | Novel compounds |
GB2189698A (en) * | 1986-04-30 | 1987-11-04 | Haessle Ab | Coated omeprazole tablets |
JPH0768125B2 (ja) * | 1988-05-18 | 1995-07-26 | エーザイ株式会社 | 酸不安定化合物の内服用製剤 |
SE9302396D0 (sv) * | 1993-07-09 | 1993-07-09 | Ab Astra | A novel compound form |
SE9302395D0 (sv) * | 1993-07-09 | 1993-07-09 | Ab Astra | New pharmaceutical formulation |
-
1993
- 1993-07-09 SE SE19939302395A patent/SE9302395D0/xx unknown
-
1994
- 1994-07-01 IL IL11018994A patent/IL110189A0/xx not_active IP Right Cessation
- 1994-07-01 HR HR940386A patent/HRP940386B1/xx not_active IP Right Cessation
- 1994-07-03 DZ DZ940072A patent/DZ1794A1/fr active
- 1994-07-04 SA SA94150057A patent/SA94150057B1/ar unknown
- 1994-07-06 IS IS4187A patent/IS2034B/is unknown
- 1994-07-07 MY MYPI94001776A patent/MY128809A/en unknown
- 1994-07-07 EG EG40894A patent/EG22373A/xx active
- 1994-07-07 ZA ZA944934A patent/ZA944934B/xx unknown
- 1994-07-07 MA MA23568A patent/MA23258A1/fr unknown
- 1994-07-08 HU HU9503874A patent/HU226779B1/hu unknown
- 1994-07-08 BR BR9406941A patent/BR9406941A/pt not_active Application Discontinuation
- 1994-07-08 SI SI9430438T patent/SI0706378T1/xx unknown
- 1994-07-08 MX MX9405219A patent/MX9405219A/es unknown
- 1994-07-08 TN TNTNSN94078A patent/TNSN94078A1/fr unknown
- 1994-07-08 CZ CZ199670A patent/CZ290323B6/cs not_active IP Right Cessation
- 1994-07-08 KR KR1019960700052A patent/KR100350203B1/ko not_active IP Right Cessation
- 1994-07-08 RU RU96102154/14A patent/RU2138254C9/ru active
- 1994-07-08 NZ NZ268694A patent/NZ268694A/en not_active IP Right Cessation
- 1994-07-08 ES ES94921155T patent/ES2191682T3/es not_active Expired - Lifetime
- 1994-07-08 EP EP94921155A patent/EP0706378B1/en not_active Expired - Lifetime
- 1994-07-08 WO PCT/SE1994/000681 patent/WO1995001783A1/en active IP Right Grant
- 1994-07-08 DE DE69432076T patent/DE69432076T2/de not_active Expired - Lifetime
- 1994-07-08 DK DK94921155T patent/DK0706378T3/da active
- 1994-07-08 UA UA96010058A patent/UA43342C2/uk unknown
- 1994-07-08 JP JP50400695A patent/JP3665334B2/ja not_active Expired - Lifetime
- 1994-07-08 SG SG1996003536A patent/SG52365A1/en unknown
- 1994-07-08 PL PL94312441A patent/PL175210B1/pl unknown
- 1994-07-08 YU YU43794A patent/YU49199B/sh unknown
- 1994-07-08 AT AT94921155T patent/ATE231719T1/de active
- 1994-07-08 US US08/313,036 patent/US5690960A/en not_active Expired - Lifetime
- 1994-07-08 AU AU71982/94A patent/AU681686B2/en not_active Expired
- 1994-07-08 CA CA002166483A patent/CA2166483C/en not_active Expired - Lifetime
- 1994-07-08 CN CN94192734A patent/CN1126946A/zh active Pending
- 1994-07-08 SK SK21-96A patent/SK281105B6/sk not_active IP Right Cessation
- 1994-11-17 EE EE9400419A patent/EE03148B1/xx unknown
-
1996
- 1996-01-05 NO NO19960067A patent/NO315146B1/no not_active IP Right Cessation
- 1996-01-09 FI FI960102A patent/FI114008B/fi not_active IP Right Cessation
-
1998
- 1998-07-17 HK HK98109229A patent/HK1008299A1/xx not_active IP Right Cessation
-
2004
- 2004-01-22 LV LVP-04-07A patent/LV13140B/en unknown
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
BR9406941A (pt) | Formulação oral com revestimento entèrico processo para a preparação da formulação processo para a inibição da secreção de acido gástrico em mamiferos e no homem e processo para o tratamento de doencas relacionados ao ácidos gástrico em mamiferos e no homem | |
ATE204178T1 (de) | Methode zur behandlung und vorbeugung von typ-1 diabetis durch orale verabreichung von insulin | |
GR861803B (en) | Novel carbonic acid derivatives method for their preparation their use and medicine containing them | |
IL125819A0 (en) | Morphine and diamorphine salts of anionic non-narcotic analgesics of the substituted carboxylic acid type processes for the preparation thereof and pharmaceutical compositions containing the same | |
DE3878111D1 (de) | Bisphenylalkylpiperazin-derivate, verfahren zur herstellung und arzneimittelzubereitung. | |
ATE143947T1 (de) | N-acylpyrrolidine und arzneimittel zur behandlung oder prophylaxe von mit ckk und gastrin in zusammenhang stehenden krankheiten | |
FI925944A0 (fi) | Arylalkylestrar av 4,5-dihydroxi-9,10-dihydro-9,10-dioxo-2-antracenkarboxylsyra med terapeutisk effekt | |
IL88726A0 (en) | Dihydrothienobenzodiazepinone derivatives,pharmaceutical compositions containing the same and processes for the preparation thereof | |
PT98764A (pt) | Processo para a preparacao de composicoes contendo factor de desenvolvimento de insulina 1 completo para o tratamento terapeutico ou profilactico de estado catabolicos | |
UA15281A (uk) | Спосіб лікуваhhя хроhічhої ішемічhої хвороби серця |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
EG | Technical examination (opinion): publication of technical examination (opinion) | ||
FC | Decision: refusal |